PBM Concerns Compete With Democrats’ Unease Over US FDA Pivots, MFN Deals

 
• By Cathy Kelly
  
The committee hearing demonstrated interest in further PBM reforms, but a lack of consensus on a path forward. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from PBMs

More from Market Access